MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm9061969

Медицинская библиотека · Journal of clinical medicine · 2020

Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up.

Kozieł Monika, Mazurek Michał, Teutsch Christine, Diener Hans-Christoph, Dubner Sergio J, Halperin Jonathan L, Ma Chang-Sheng, Rothman Kenneth J, Brandes Axel, Paquette Miney, Zint Kristina, França Lionel Riou, Lu Shihai, Bartels Dorothee B, Huisman Menno V, Lip Gregory Y H

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once daily (QD) vs. twice daily (BID)).

METHODS

Consecutive patients were followed for 1 year in phase III of the GLORIA-AF registry. Drug persistence was defined as the use of OAC without any discontinuation in >30 days or switching to alternative therapy.

RESULTS

Among 21,109 eligible patients in phase III, 17,266 patients who were prescribed OAC at baseline and those who took ≥1 OAC dose were included. The 1-year proportion of patients receiving NOAC and VKA who persisted on treatment was 80% and 75%, respectively. The 1-year persistence with NOACs BID and NOACs QD was 81% and 80%, respectively. Female gender, hypertension, older age, alcohol use, permanent, asymptomatic, and minimally symptomatic AF were associated with better OAC persistence. Region, medication usage predisposing to bleeding, being a current smoker, treatment reimbursement, and proton pump inhibitors were associated with lower OAC persistence.

CONCLUSIONS

Drug persistence was higher with NOACs (1-year persistence was 80%) than with VKAs (75%). There was little difference in 1-year persistence between NOAC dosing regimens.

Для цитирования: Kozieł Monika, Mazurek Michał, Teutsch Christine, Diener Hans-Christoph, Dubner Sergio J, Halperin Jonathan L, Ma Chang-Sheng, Rothman Kenneth J, Brandes Axel, Paquette Miney, Zint Kristina, França Lionel Riou, Lu Shihai, Bartels Dorothee B, Huisman Menno V, Lip Gregory Y H. Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up.. Journal of clinical medicine. 2020. DOI: 10.3390/jcm9061969.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.